Pfizer and Bristol-Myers Squibb Could Face a Big Threat from Small Biotech Exelixis
Oct 17, 2016, 10:08 AM
by
Michael Croft
The Motley Fool | On Oct. 10, Exelixis announced results from its phase 2 CABOSUN study of Cabometyx in patients with previously untreated advanced kidney cancer. This clinical trial was structured as a head-to-head comparison between Cabometyx and Pfizer's Sutent, and Cabometyx emerged as the clear winner.
October 17, 2016 | On Oct. 10, Exelixis announced results from its phase 2 CABOSUN study of Cabometyx in patients with previously untreated advanced kidney cancer. This clinical trial was structured as a head-to-head comparison between Cabometyx and Pfizer's Sutent, and Cabometyx emerged as the clear winner. The Motley Fool